CymaBay Therapeutics Inc (CBAY) stock is higher by 288.00% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver’s proprietary ranking system, gives CBAY stock a score of 66 out of a possible 100.
That rank is influenced by a fundamental score of 95. In addition to the average rating from Wall Street analysts, CBAY stock has a mean target price of 12.909. This means analysts expect the stock to increase 121.80% over the next 12 months. CBAY's rank also includes a short-term technical score of 92. The long-term technical score for CBAY is 10.
What's Happening with CBAY Stock Today
CymaBay Therapeutics Inc (CBAY) stock has fallen -3.41% while the S&P 500 is higher by 0.12% as of 3:18 PM on Friday, Feb 12. CBAY is down -$0.20 from the previous closing price of $6.02 on volume of 1,498,974 shares. Over the past year the S&P 500 has gained 16.21% while CBAY is higher by 288.00%. CBAY lost -$0.94 per share in the over the last 12 months.
Click Here to get the full Stock Score Report on CymaBay Therapeutics Inc (CBAY) Stock.
